recommendation

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS ScotlandSanthera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in…

2 months ago
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX to 800 Patients with a Concurrent Private Placement of up to $41 MillionPolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX to 800 Patients with a Concurrent Private Placement of up to $41 Million

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX to 800 Patients with a Concurrent Private Placement of up to $41 Million

December 23, 2024 19:22 ET  | Source: PolyPid Ltd. • 630 Patients Enrolled To Date; Enrollment Completion Now Expected in…

3 months ago
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities…

4 months ago